Bridget Keenan

Bridget Keenan practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Bridget Keenan's NPI, 1497175798, was assigned on April 24, 2014. Bridget Keenan graduated from The Johns Hopkins University School of Medicine in 2015. Bridget Keenan holds California license A145542.

Bridget Keenan's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Bridget Keenan's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Bridget Keenan to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Bridget Keenan practices. Vendor and product names are available with a free account.

Medical oncology is Bridget Keenan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Bridget Keenan is board certified in medical oncology by the American Board of Internal Medicine. Bridget Keenan is licensed in California.

Dmand AI lists lung cancer and prostate cancer among the conditions Bridget Keenan treats.

CMS data shows 175 Medicare services from Bridget Keenan across 4 procedure codes in 2024, for 54 Medicare patients. Medicare paid $13,516 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 54 Medicare patients who saw Bridget Keenan in 2024. The largest group is 65 to 74, with 37 patients. 65% of them have cancer, and 57% have high blood pressure. 20% are also on Medicaid. Their average risk score is 2.89, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Bridget Keenan's median patient age at 60, with 55% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Bridget Keenan for performance year 2024, reported as part of a group. Bridget Keenan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Bridget Keenan as offering telehealth.

Dmand AI links 22 papers to Bridget Keenan, published from 2005 to 2024. 2020 was the busiest year, with 3. The most frequent topics are Immunotherapy, Leadership and Antibodies, Monoclonal. Bridget Keenan has published most often in Cancer Res Commun. Bridget Keenan's most frequent co-authors are Elizabeth Jaffee, MD, Lekshmi Santhosh, MD and Elizabeth Susan Harleman, MD.

Dmand AI links Bridget Keenan to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Colonic Neoplasms, Lymphoma, T-Cell, Peripheral and Squamous Cell Carcinoma of Head and Neck. Open Payments lists research payments to Bridget Keenan that name 1 trial.

CMS Open Payments shows 12 general payments to Bridget Keenan from 3 drug and device companies from 2022 to 2025. Travel and lodging make up the largest share, 80% of the total. Genentech, Inc. paid the most, $12,216. It also lists 3 research payments totaling $1,066 in 2025, naming 1 clinical trial.

Bridget Keenan graduated from The Johns Hopkins University School of Medicine in 2015.

Bridget Keenan is in network with 7 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.